ABSTRACT
BACKGROUND: The effectiveness of platelet-rich plasma (PRP) injections for osteoarthritis (OA) is still controversial. We investigated the effect of PRP injections in patients with knee OA based on decreasing pain, improving function, global assessment and changes regarding joint imaging. METHODS: We performed a comprehensive, systematic literature search in computerised databases (MEDLINE, EMBASE, CINAHL, CENTRAL, Web of Science and PEDro) until June 2014 for randomised or non-randomised controlled trials. These were graded for risk of bias and a level of evidence was provided. If possible, meta-analysis was performed. RESULTS: Ten trials were included. In these, intra-articular PRP injections were more effective for pain reduction (mean difference (MD) -2.45; 95% CI -2.92 to -1.98; p value <0.00001 and MD -2.07; 95% CI -2.59 to -1.55; p value <0.00001, single and double PRP injections, respectively) compared with placebo at 6 months postinjection. Intra-articular PRP injections were compared with hyaluronic acid and showed a statistically significant difference in favour of PRP on pain reduction based on the visual analogue scale and numeric rating scale (standardised mean difference -0.92; 95% CI -1.20 to -0.63; p value <0.00001) at 6 months postinjection. Almost all trials revealed a high risk of bias. CONCLUSIONS: On the basis of the current evidence, PRP injections reduced pain more effectively than did placebo injections in OA of the knee (level of evidence: limited due to a high risk of bias). This significant effect on pain was also seen when PRP injections were compared with hyaluronic acid injections (level of evidence: moderate due to a generally high risk of bias). Additionally, function improved significantly more when PRP injections were compared with controls (limited to moderate evidence). More large randomised studies of good quality and low risk of bias are needed to test whether PRP injections should be a routine part of management of patients with OA of the knee.
Subject(s)
Osteoarthritis, Knee/therapy , Platelet-Rich Plasma , Clinical Trials as Topic , Humans , Injections, Intra-Articular , Middle Aged , Pain/etiology , Patient Satisfaction , Quality Assurance, Health Care , Treatment OutcomeSubject(s)
Granuloma/chemically induced , Quinoxalines/adverse effects , Uveitis/chemically induced , Administration, Topical , Aged , Aged, 80 and over , Brimonidine Tartrate , Female , Glaucoma/drug therapy , Granuloma/complications , Humans , Ophthalmic Solutions/adverse effects , Quinoxalines/administration & dosage , Uveitis/complicationsABSTRACT
In 12 known multiple sclerosis patients with a visual acuity of 7/10 or better in both eyes, optic nerve function was tested by means of contrast sensitivity measurement (VISTECH technique) and pattern-VEP. The results were compared with those of an age related control group. The VISTECH contrast sensitivity measurement is a useful tool in evaluating the remaining visual discomfort after the resolution of an optic neuritis. However, to detect a subclinical optic neuritis, the pattern-VEP is more sensitive.
